Furtehrmore, PSA, PSMA, and 5T4 were found to decrease after therapy, suggesting that PCa markers in EVs have the potential as biomarkers for monitoring patients post-therapy. The gene discussed is FOLH1; the disease is posterior cortical atrophy.